Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Update

Plus Therapeutics, Inc. (NASDAQ:PSTV) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 23,932,707 shares, a growth of 19.0% from the March 15th total of 20,108,546 shares. Approximately 351.5% of the company’s stock are short sold. Based on an average daily volume of 5,057,822 shares, the short-interest ratio is currently 4.7 days.

Plus Therapeutics Stock Up 7.4%

Plus Therapeutics stock traded up $0.44 during trading hours on Friday, hitting $6.39. The company had a trading volume of 254,192 shares, compared to its average volume of 584,082. The firm’s fifty day moving average is $6.14 and its 200-day moving average is $10.92. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $30.50.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Thursday, March 12th. The company reported $6.25 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $6.28. The company had revenue of $1.37 million during the quarter, compared to analyst estimates of $1.23 million. On average, research analysts predict that Plus Therapeutics will post -2.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of PSTV. Jane Street Group LLC bought a new stake in Plus Therapeutics in the 2nd quarter valued at $41,000. Susquehanna International Group LLP acquired a new stake in shares of Plus Therapeutics during the 3rd quarter worth about $46,000. Scientech Research LLC acquired a new stake in shares of Plus Therapeutics during the 3rd quarter worth about $100,000. XTX Topco Ltd acquired a new stake in shares of Plus Therapeutics during the 4th quarter worth about $127,000. Finally, State Street Corp increased its position in shares of Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after purchasing an additional 127,000 shares in the last quarter. Institutional investors and hedge funds own 3.28% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PSTV shares. D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Wall Street Zen upgraded shares of Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. HC Wainwright restated a “buy” rating and issued a $25.00 target price (down from $50.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Thursday, January 22nd. Finally, Ascendiant Capital Markets cut their target price on shares of Plus Therapeutics from $475.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Plus Therapeutics has a consensus rating of “Hold” and a consensus target price of $58.00.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.